One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Olaparib is a small molecule inhibitor of ADP ribose polymerase (PARP) with potential chemical sensitization, radiosensitization, and anti-tumor activity. Olaparib selectively binds and inhibits PARP, inhibiting PARP mediated repair of single stranded DNA breaks; The inhibition of PARP may enhance the cytotoxicity of DNA disruptors and potentially reverse the chemotherapy and radiation resistance of tumor cells. PARP catalyzes post-translational ADP nucleosylation of nuclear proteins, which can be activated by single stranded DNA cleavage.
One year of qualification
Audited Supplier
Pharma Sources Insight January 2025
![(6S) -5 - tert-butyl oxycarbonyl - 5 - n hybrid - [2.4] -heptane - 5-carboxylic acid](https://eimg.pharmasources.com/img_Cphi_en/Product/2017_07/Mimg_1707171039608722.jpg!145)
![(3aR,4R,6S,6aS)-methyl 4-(tert-butoxycarbonyl)-3-(pentan-3-yl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]](https://eimg.pharmasources.com/img_Cphi_en/Product/2017_09/Mimg_1709071120622427.jpg!145)
